JBJonine L. Bernstein

Jonine L. Bernstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonine L. Bernstein has a total of 159 co-authors. Here are the top co-authors by number of shared publications:

  • Anne S. Reiner

    Memorial Sloan Kettering Cancer Center, New York, New York, USA

    7 shared publications
  • Charles F. Lynch

    Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA

    7 shared publications
  • Kathleen E. Malone

    Epidemiology Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    7 shared publications
  • Patrick Concannon

    Genetics Institute and Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL

    7 shared publications
  • Xiaolin Liang

    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    7 shared publications
  • Esther M. John

    Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA

    6 shared publications

Latest Publications

  • Open Access

    Evaluating mammographic density polygenic risk score for contralateral breast cancer risk prediction

    by Elnaz Naderi, Gordon P. Watt, Julia A. Knight, Kathleen E. Malone, Charles F. Lynch, Esther M. John, Xiang Shu, Tuong L. Nguyen, Jung Hun Oh, Meghan Woods, et al.

    The online version contains supplementary material available at 10.1038/s41598-026-42365-7.

  • Open Access

    A genome-wide association study of contralateral breast cancer in the Women’s Environmental Cancer and Radiation Epidemiology Study

    by Xiaohui Sun, Anne S. Reiner, Anh Phong Tran, Gordon P. Watt, Jung Hun Oh, Lene Mellemkjær, Charles F. Lynch, Julia A. Knight, Esther M. John, Kathleen E. Malone, et al.

    Background: Contralateral breast cancer (CBC) is the most common second primary cancer diagnosed in breast cancer survivors, yet the understanding of the genetic susceptibility of CBC, particularly with respect to common variants, remains incomplete. This study aimed to investigate the genetic basis of CBC to better understand this malignancy. Findings: We performed a genome-wide association analysis in the Women’s Environmental Cancer and Radiation Epidemiology (WECARE) Study of women with first breast cancer diagnosed at age < 55 years including 1161 with CBC who served as cases and 1668 with unilateral breast cancer (UBC) who served as controls. We observed two loci (rs59657211, 9q32, SLC31A2/FAM225A and rs3815096, 6p22.1, TRIM31) with suggestive genome-wide significant associations (P < 1 × 10–6). We also found an increased risk of CBC associated with a breast cancer-specific polygenic risk score (PRS) comprised of 239 known breast cancer susceptibility single nucleotide polymorphisms (SNPs) (rate ratio per 1-SD change: 1.25; 95% confidence interval 1.14–1.36, P < 0.0001). The protective effect of chemotherapy on CBC risk was statistically significant only among patients with an elevated PRS (Pheterogeneity = 0.04). The AUC that included the PRS and known breast cancer risk factors was significantly elevated. Conclusions: The present GWAS identified two previously unreported loci with suggestive genome-wide significance. We also confirm that an elevated risk of CBC is associated with a comprehensive breast cancer susceptibility PRS that is independent of known breast cancer risk factors. These findings advance our understanding of genetic risk factors involved in CBC etiology.


  • Trends in Radiation Dose to the Contralateral Breast During Breast Cancer Radiation Therapy

    by Gordon P. Watt, Susan A. Smith, Rebecca M. Howell, Angélica Pérez-Andújar, Anne S. Reiner, Laura Cerviño, Beryl McCormick, Daniela Hess, Julia A. Knight, Kathleen E. Malone, et al.

    Over 4 million survivors of breast cancer live in the United States, 35% of whom were treated before 2009. Approximately half of patients with breast cancer receive radiation therapy, which exposes the untreated contralateral breast to radiation and increases the risk of a subsequent contralateral breast cancer (CBC). Radiation oncology has strived to reduce unwanted radiation dose, but it is unknown whether a corresponding decline in actual dose received to the untreated contralateral breast has occurred. The purpose of this study was to evaluate trends in unwanted contralateral breast radiation dose to inform risk assessment of second primary cancer in the contralateral breast for long-term survivors of breast cancer. Individually estimated radiation absorbed doses to the four quadrants and areola central area of the contralateral breast were estimated for 2,132 women treated with radiation therapy for local/regional breast cancers at age 1 Gy for women <40 years of age was 17%. Radiation dose-reduction measures have reduced dose to the contralateral breast during breast radiation therapy. Reducing the dose to the contralateral breast to <1 Gy could prevent an estimated 17% of subsequent radiation-associated CBCs for women treated under 40 years of age. These dose estimates inform CBC surveillance for the growing number of breast cancer survivors who received radiation therapy as young women in recent decades. Continued reductions in dose to the contralateral breast could further reduce the incidence of radiation-associated CBC.


  • Open Access

    The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women

    by Alexey Larionov, Eleanor Fewings, James Redman, Mae Goldgraben, Graeme Clark, John Boice, Patrick Concannon, Jonine Bernstein, David V. Conti, the WECARE Study Collaborative Group, et al.

    Background: Contralateral breast cancer (CBC) is associated with younger age at first diagnosis, family history and pathogenic germline variants (PGVs) in genes such as BRCA1, BRCA2 and PALB2. However, data regarding genetic factors predisposing to CBC among younger women who are BRCA1/2/PALB2-negative remain limited. Methods: In this nested case-control study, participants negative for BRCA1/2/PALB2 PGVs were selected from the WECARE Study. The burden of PGVs in established breast cancer risk genes was compared in 357 cases with CBC and 366 matched controls with unilateral breast cancer (UBC). The samples were sequenced in two phases. Whole exome sequencing was used in Group 1, 162 CBC and 172 UBC (mean age at diagnosis: 42 years). A targeted panel of genes was used in Group 2, 195 CBC and 194 UBC (mean age at diagnosis: 50 years). Comparisons of PGVs burdens between CBC and UBC were made in these groups, and additional stratified sub-analysis was performed within each group according to the age at diagnosis and the time from first breast cancer (BC). Results: The PGVs burden in Group 1 was significantly higher in CBC than in UBC (p = 0.002, OR = 2.5, 95CI: 1.2–5.6), driven mainly by variants in CHEK2 and ATM. The proportions of PGVs carriers in CBC and UBC in this group were 14.8% and 5.8%, respectively. There was no significant difference in PGVs burden between CBC and UBC in Group 2 (p = 0.4, OR = 1.4, 95CI: 0.7–2.8), with proportions of carriers being 8.7% and 8.2%, respectively. There was a significant association of PGVs in CBC with younger age. Metanalysis combining both groups confirmed the significant association between the burden of PGVs and the risk of CBC (p = 0.006) with the significance driven by the younger cases (Group 1). Conclusion: In younger BRCA1/BRCA2/PALB2-negative women, the aggregated burden of PGVs in breast cancer risk genes was associated with the increased risk of CBC and was inversely proportional to the age at onset.


  • Open Access

    Radiation disasters – long term consequences: reflections and summary of a recent symposium

    by Julie J. Burtt, Suminori Akiba, Dimitry Bazyka, C. Norman Coleman, Maureen Hatch, Jonine L. Bernstein

    One of the most compelling challenges in radiation epidemiology is the scientific evaluation of the long-term health consequences following nuclear radiation disasters. The most significant events ...


  • Open Access

    A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study

    by Jennifer D. Brooks, John D. Boice, Roy E. Shore, Anne S. Reiner, Susan A. Smith, Leslie Bernstein, Julia A. Knight, Charles F. Lynch, Esther M. John, Kathleen E. Malone, et al.


  • Open Access

    Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer

    by Gordon P. Watt, Anne S. Reiner, Susan A. Smith, Daniel O. Stram, Marinela Capanu, Kathleen E. Malone, Charles F. Lynch, Esther M. John, Julia A. Knight, Lene Mellemkjær, et al.

    Survivors of invasive breast cancer have a high risk of developing asynchronous contralateral breast cancer.1,2 This risk is increased among women who are relatively young when they receive the first diagnosis,3,4 have a family history of breast cancer,5,6 or have high-penetrance mutations.7-9 Treatment with tamoxifen, aromatase inhibitors, or chemotherapy is associated with reduced risk of contralateral breast cancer,10-13 while stray radiation doses received to the contralateral breast during radiation therapy of the first primary tumor are associated with increased risk.14 Although radiation therapy is an effective cancer treatment, stray radiation during radiation therapy produces potentially carcinogenic DNA damage in unaffected tissue. Radiation exposure induces a variety of lesions in DNA, the most dangerous of which are DNA double strand breaks. In humans, double strand breaks are repaired primarily by the relatively error-prone nonhomologous end-joining (NHEJ) pathway, whereas the less error-prone homologous recombination pathway is active mainly during the G2 phase of actively cycling cells.15 Research has shown that mutations in DNA damage response genes are associated with hypersensitivity to ionizing radiation and a high incidence of cancer.16 Additionally, a 2007 study17 among Taiwanese women found that variants in 2 genes within the NHEJ pathway were associated with breast cancer risk. As breast cancer is the most common malignant neoplasm among women in the United States18 and radiation therapy is used to treat more than half of women with breast cancer,19 identifying risk factors for radiation-associated contralateral breast cancer is an important issue.


  • Open Access

    CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

    by The WECARE Study collaborative group, Jennifer D. Brooks, Elizabeth A. Comen, Anne S. Reiner, Irene Orlow, Siok F. Leong, Xiaolin Liang, Lene Mellemkjær, Julia A. Knight, Charles F. Lynch, et al.

    Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its active metabolites, and variants in this gene have been associated with reduced tamoxifen metabolism. The impact of variation on risk of contralateral breast cancer (CBC) is unknown. Germline DNA from 1514 CBC cases and 2203 unilateral breast cancer controls was genotyped for seven single nucleotide polymorphisms, one three-nucleotide insertion-deletion, and a full gene deletion. Each variant has an expected impact on enzyme activity, which in combination allows for the classification of women as extensive, intermediate, and poor metabolizers (EM, IM, and PM respectively). Each woman was assigned one of six possible diplotypes and a corresponding CYP2D6 activity score (AS): EM/EM (AS = 2), EM/IM (AS = 1.5), EM/PM (AS = 1), IM/IM (AS = 0.75), IM/PM (AS = 0.5), and PM/PM (AS = 0). We also collapsed categories of the AS to generate an overall phenotype (EM, AS ≥ 1; IM, AS = 0.5–0.75; PM, AS = 0). Rate ratios (RRs) and 95% confidence intervals (CIs) for the association between tamoxifen treatment and risk of CBC in our study population were estimated using conditional logistic regression, stratified by AS. Among women with AS ≥ 1 (i.e., EM), tamoxifen treatment was associated with a 20–55% reduced RR of CBC (AS = 2, RR = – 0.81, 95% CI 0.62–1.06; AS = 1.5, RR = 0.45, 95% CI 0.30–0.68; and AS = 1, RR = 0.55, 95% CI 0.40–0.74). Among women with no EM alleles and at least one PM allele (i.e., IM and PM), tamoxifen did not appear to impact the RR of CBC in this population (AS = 0.5, RR = 1.08, 95% CI 0.59–1.96; and AS = 0, RR = 1.17, 95% CI 0.58–2.35) (p for homogeneity = – 0.02). This study suggests that the CYP2D6 phenotype may contribute to some of the observed variability in the impact of tamoxifen treatment for a first breast cancer on risk of developing CBC.


  • Open Access

    The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study

    by WECARE Study Collaborative Group, Julia A. Knight, Kristina M. Blackmore, Jing Fan, Kathleen E. Malone, Esther M. John, Charles F. Lynch, Celine M. Vachon, Leslie Bernstein, Jennifer D. Brooks, et al.

    Mammographic density (MD) is an established predictor of risk of a first breast cancer, but the relationship of MD to contralateral breast cancer (CBC) risk is not clear, including the roles of age, mammogram timing, and change with treatment. Multivariable prediction models for CBC risk are needed and MD could contribute to these. We conducted a case-control study of MD and CBC risk in phase II of the WECARE study where cases had a CBC diagnosed ≥ 2 years after first diagnosis at age <55 years and controls had unilateral breast cancer (UBC) with similar follow-up time. We retrieved film mammograms of the unaffected breast from two time points, prior to/at the time of the first diagnosis (253 CBC cases, 269 UBC controls) and ≥ 6 months up to 48 months following the first diagnosis (333 CBC cases, 377 UBC controls). Mammograms were digitized and percent MD (%MD) was measured using the thresholding program Cumulus. Odds ratios (OR) and 95% confidence intervals (CI) for association between %MD and CBC, adjusted for age, treatment, and other factors related to CBC, were estimated using logistic regression. Linear regression was used to estimate the association between treatment modality and change in %MD in 467 women with mammograms at both time points. For %MD assessed following diagnosis, there was a statistically significant trend of increasing CBC with increasing %MD (p = 0.03). Lower density (<25%) was associated with reduced risk of CBC compared to 25 to < 50% density (OR 0.69, 95% CI 0.49, 0.98). Similar, but weaker, associations were noted for %MD measurements prior to/at diagnosis. The relationship appeared strongest in women aged < 45 years and non-existent in women aged 50 to 54 years. A decrease of ≥ 10% in %MD between first and second mammogram was associated marginally with reduced risk of CBC (OR 0.63, 95% CI 0.40, 1.01) compared to change of <10%. Both tamoxifen and chemotherapy were associated with statistically significant 3% decreases in %MD (p < 0.01). Post-diagnosis measures of %MD may be useful to include in CBC risk prediction models with consideration of age at diagnosis. Chemotherapy is associated with reductions in %MD, similar to tamoxifen.


  • ATM, radiation, and the risk of second primary breast cancer

    by Jonine L. Bernstein, WECARE Study Collaborative Group, Patrick Concannon

    Purpose: It was first suggested more than 40 years ago that heterozygous carriers for the human autosomal recessive disorder Ataxia-Telangiectasia (A-T) might also be at increased risk for cancer. Subsequent studies have identified the responsible gene, Ataxia-Telangiectasia Mutated (ATM), characterized genetic variation at this locus in A-T and a variety of different cancers, and described the functions of the ATM protein with regard to cellular DNA damage responses. However, an overall model of how ATM contributes to cancer risk, and in particular, the role of DNA damage in this process, remains lacking. This review considers these questions in the context of contralateral breast cancer (CBC). Conclusions: Heterozygous carriers of loss of function mutations in ATM that are A-T causing, are at increased risk of breast cancer. However, examination of a range of genetic variants, both rare and common, across multiple cancers, suggests that ATM may have additional effects on cancer risk that are allele-dependent. In the case of CBC, selected common alleles at ATM are associated with a reduced incidence of CBC, while other rare and predicted deleterious variants may act jointly with radiation exposure to increase risk. Further studies that characterize germline and somatic ATM mutations in breast cancer and relate the detected genetic changes to functional outcomes, particularly with regard to radiation responses, are needed to gain a complete picture of the complex relationship between ATM, radiation and breast cancer.